Atsena closes $150m in Series C round to progress gene therapy
Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of its lead gene…
All articles by
-
-
FDA grants accelerated approval to Novartis’ Vanrafia for IgAN
The US Food and Drug Administration (FDA) has granted accelerated approval to Novartis’ Vanrafia, a treatment aimed at decreasing proteinuria…
-
Astellas Pharma and JFCR partner for oncology research
Astellas Pharma has entered a strategic partnership with the Japanese Foundation for Cancer Research (JFCR) to expedite research in translational…
-
Organon acquires Actemra biosimilar’s US rights from Biogen
Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence,…
-
Amneal and Shilpa introduce Boruzu in US for cancer treatment
Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a…
-
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases
Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of priority review…
-
BioVersys secures patent claims in China for BV100
Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous formulation of rifabutin.…
-
Apollomics and LaunXP agree on NSCLC treatment in Asia
Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined with an epidermal…
-
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as…
-
Macau approves IASO Bio’s multiple myeloma therapy
The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene autoleucel…